FDA warning letters to foreign manufacturers jump 40%; Novartis turns to CMO to meet demands;

> The FDA sent 52 GMP warning letters in the last 12 months, and 40% of those were to manufacturing plants outside the U.S. Story

> Novartis ($NVS) is using some contract manufacturing operations to help it meet drug demands while its plant in Nebraska continues remediation. Story

> The FDA has sent letters to more than four dozen doctors and medical practices in the U.S. warning them they may have purchased counterfeit Avastin, which, if used, could harm patients. Story

> Spectrum Pharmaceuticals ($SPPI) says it has increased its manufacturing capacity for cancer treatment Fusilev (levoleucovorin) for injection. Item

> Novasep, which makes pharma purification systems, has named Jean-Claude Romain director of quality and placed him on the company's executive committee. Release

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.